✨ Free AI Report
Vir Biotechnology, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Vir Biotechnology, Inc.
Company Research

Vir Biotechnology, Inc.: Business Overview, Financials & Competitive Analysis

Vir Biotechnology, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Pivoting to oncology with landmark partnerships and strong clinical data while maintaining infectious disease portfolio, supported by extended cash runway to 2028. Vir reported Q1 2026 net loss of $125.7 million, representing a 4% increase year-over-year. However, the company shows strong clinical momentum with positive Phase 1 data for.

What is Vir Biotechnology, Inc.'s industry? Vir Biotechnology, Inc. (vir.bio) operates in Immunology Drugs. AskCyborg classifies Vir Biotechnology, Inc. under Immunology Drugs in its company registry.

Vir Biotechnology is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. The company ...

7/ 10Strong

Cyborg Score thesis

Pivoting to oncology with landmark partnerships and strong clinical data while maintaining infectious disease portfolio,...

Read the full analyst-debate transcript →
Industry Immunology Drugs
5 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Vir Biotechnology, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Vir Biotechnology, Inc.

AskCyborg analysts argue the bull and bear cases for Vir Biotechnology, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Vir Biotechnology, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Vir Biotechnology, Inc. Overview

Pro stress-test →

Vir Biotechnology is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. The company is positioning itself as a leader in masked T-cell engager immunotherapy while maintaining its hepatitis delta franchise.

Strategic Profile

Pro stress-test →

The company has executed two landmark collaborations worth up to $2.2 billion combined. In April 2026, the global strategic collaboration with Astellas to advance the PSMA-targeted dual-masked T-cell engager VIR-5500 closed with the first patient dosed in Phase 1 dose-expansion cohorts. Strategic partnerships and financing have extended cash runway to 2028.

Competitive Landscape

Pro stress-test →

Competitors include Rigel Pharmaceuticals, Allogene Therapeutics, Adaptimmune Therapeutics, Sorrento Therapeutics, and Synlogic. Vir differentiates itself through its dual masked T-cell engager platform across both infectious disease and oncology indications, with particularly strong clinical progress in hepatitis delta and prostate cancer.

Industry Context

Vir Biotechnology, Inc. operates in Immunology Drugs.

Key facts

Headquarters: San Francisco, US · Revenue: $64.7 million trailing twelve-month revenue as of March 31, 2026 · Market cap: $1.56 billion as of May 7, 2026

What the analysts stress-tested

The top findings that survived the multi-agent debate for Vir Biotechnology, Inc..

  • Global collaboration with Astellas worth up to $315 million upfront plus equity investment for VIR-5500 closed in April 2026 with first patient dosed in Phase 1 expansion cohorts
  • Phase 2 SOLSTICE data for chronic hepatitis delta combination therapy showed 77% achieved undetectable hepatitis delta virus RNA at Week 72, increasing to 88% at Week 96
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • May 2026Closed global strategic collaboration with Astellas for VIR-5500 prostate cancer program with $315 million upfront payment
  • May 2026Presented positive Phase 1 VIR-5500 data at ASCO Genitourinary Cancers Symposium showing dose-dependent anti-tumor activity
  • +2 moreTrack every material event for Vir Biotechnology, Inc. as it happens. Explore monitoring →
Get alerted when Vir Biotechnology, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Rigel PharmaceuticalsClinical-stage biopharmaceutical company→Allogene TherapeuticsCell therapy development→Adaptimmune TherapeuticsT-cell immunotherapy→Sorrento TherapeuticsImmunotherapy platform→SynlogicSynthetic biology therapeutics→

Compare Vir Biotechnology, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Vir Biotechnology, Inc. operates in Immunology Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Immunology Drugs research →
NEW · MCP server

Ask your AI assistant about Vir Biotechnology, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Vir Biotechnology, Inc. and its top competitor on Cyborg Score”
“What did Vir Biotechnology, Inc. do this quarter?”
“Is Vir Biotechnology, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Vir Biotechnology, Inc. do?+
Vir Biotechnology is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. The company ...
What is Vir Biotechnology, Inc.'s Cyborg Score?+
Vir Biotechnology, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Vir Biotechnology, Inc.'s main competitors?+
Named competitors include Rigel Pharmaceuticals, Allogene Therapeutics, Adaptimmune Therapeutics, Sorrento Therapeutics. The full competitive landscape is in the AskCyborg report.
How can I get the full Vir Biotechnology, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Vir Biotechnology, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Vir Biotechnology, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Immunology Drugs research

Companies in the same sector and named competitors, ranked by Cyborg Score.

3Synlogic, Inc.